Recombinant Proteins
Product List
BGN Human, Sf9
Biglycan Human Recombinant, Sf9
Sf9, Insect cells.
BGN Mouse
Biglycan Mouse Recombinant
Recombinant BGN, expressed in Sf9 insect cells, is a single, glycosylated polypeptide chain. This protein comprises 574 amino acids, specifically spanning from amino acid positions 38 to 369. It has a molecular mass of 64.6 kDa. However, on SDS-PAGE analysis, the apparent molecular size will appear between 50-70 kDa. The recombinant BGN is engineered to carry a 242 amino acid long hIgG-His-tag at its C-terminus. Purification of the protein is achieved using proprietary chromatographic techniques.
Sf9, Insect cells.
The product appears as a clear and colorless solution that has been sterilized by filtration.
BGN Human
Biglycan Human Recombinant
Introduction
Biglycan is a small leucine-rich proteoglycan (SLRP) that is a key component of the extracellular matrix (ECM). It belongs to the class I family of SLRPs, which are characterized by leucine-rich repeats (LRR) and glycosaminoglycan (GAG) side chains . Biglycan is encoded by the BGN gene located on the X chromosome in humans .
Key Biological Properties: Biglycan consists of a protein core with leucine-rich repeat regions and two GAG chains, typically chondroitin sulfate (CS) or dermatan sulfate (DS) .
Expression Patterns and Tissue Distribution: Biglycan is ubiquitously expressed in various ECM tissues, including bone, cartilage, and tendon . It is also found in the descending thoracic aorta, ascending aorta, right coronary artery, and other tissues .
Primary Biological Functions: Biglycan plays a crucial role in scaffolding collagen fibrils and mediating cell signaling . It is involved in bone formation, muscle integrity, and synapse stability at the neuromuscular junction .
Role in Immune Responses and Pathogen Recognition: Biglycan acts as a danger signal when released from the ECM, binding to Toll-like receptors (TLR) 2 and 4, and initiating proinflammatory signaling . This links the innate to the adaptive immune response .
Mechanisms with Other Molecules and Cells: Biglycan interacts with collagen, both via the core protein and GAG chains, and competes with decorin for the same binding site on collagen . It also interacts with TLR2/TLR4 and CD14 on macrophages, causing downstream activation and nuclear translocation of NF-κB .
Binding Partners and Downstream Signaling Cascades: Biglycan’s interaction with TLRs and CD14 triggers a cascade of proinflammatory signals, linking tissue stress or injury to immune responses .
Regulatory Mechanisms Controlling Expression and Activity: Biglycan expression is regulated at both transcriptional and post-translational levels. Dysregulation can lead to various clinical conditions, including metabolic disorders, inflammatory disorders, and malignancies .
Transcriptional Regulation and Post-Translational Modifications: The transcriptional regulation of biglycan involves various signaling pathways, while post-translational modifications include the addition of GAG chains .
Biomedical Research: Biglycan is studied for its role in various diseases, including cancer, where high expression is associated with tumor growth and metastasis .
Diagnostic Tools and Therapeutic Strategies: Biglycan’s presence in plasma is evaluated as a biomarker for inflammatory diseases . It is also considered a potential therapeutic target for treating inflammatory diseases and skeletal muscular dystrophies .
Role Throughout the Life Cycle: Biglycan is involved in bone development and regeneration, starting from embryonic development and affecting bone integrity and strength . It also plays a role in muscle integrity and synapse stability, impacting various stages of life from development to aging and disease .
